Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Microbiome - Competitive Landscape, Technology & Pipeline Analysis, 2017 - Research and Markets

Research and Markets
Posted on: 02 Aug 17

The "Microbiome - Competitive Landscape, Technology and Pipeline Analysis, 2017" drug pipelines has been added to Research and Markets' offering.

The Microbiome-Competitive Landscape, Technology and Pipeline Analysis, 2016 provides comprehensive insights about pipeline drugs across this microbiome based products.

This report provides information on the therapeutic development based on the Microbiome dealing with all the pipeline drugs, comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, IND filed, Preclinical, Discovery and unknown stages, therapeutics assessment by monotherapy and combination products and molecule type drug information.

There are in total 73 drugs in pipeline out of which 2 products is in Phase II/III, 8 products in Phase II, 6 product are in Phase I, 1 product are in Phase 0 and 1 Product in IND. Around 34 products are in Pre-clinical, 18 products are in Discovery stage of development and 3 products is in Unknown stage of development. Companies have also gone in collaboration with different partners.

The market of microbiome therapies is progressing rapidly. Various companies are getting on the action, aiming to target microbes to treat various types of diseases. Synlogic is currently developing 6 drugs that address disease by targeting gut microbiome using their synthetic biotics approach. The company is also collaborated with different partners to apply their platform to create innovative synthetic biotics for the treatment of major diseases in disease areas including inflammation, metabolism, oncology and CNS. All products of Synlogic are in Pre-Clinical and Discovery stage.

Other companies are also in race for developing the products that target the microbes. Seres therapeutics is also developing the 5 products with their lead program, SER-109 for the prevention of recurrent Clostridium difficile infections, which has granted the Breakthrough therapy by FDA.

Companies Mentioned

  • Seres Therapeutics
  • Synlogic

Key Topics Covered:

1. Executive Summary

2. Executive Summary Snapshot

3. Microbiome Overview

4. Pipeline Products Analysis

5. Pipeline Therapeutics

6. Drug 1

7. Drug 2

8. Therapeutic Assessment

9. Companies Planning for Future Development in Microbiome

10. Appendix

11. Consulting Services

12. About the Publisher

13. Contact Us

14. Disclaimer

For more information about this drug pipelines report visit

View source version on

Business Wire

Last updated on: 02/08/2017

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.